The brand name and generic drug industries once again came under congressional fire for increases in drug pricing, this time for medicines to treat opioid addiction and overdose.
The House Judiciary's Subcommittee on Regulatory Reform, Commercial and Antitrust Law held a Sept. 22 hearing on the state of...





